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Abstract
Background: Diabetes is often associated with complications and comorbidities. The purpose of
this research is to compare medical resources used by patients with the following diagnoses:
diabetes mellitus (DM), diabetic neuropathy (DN), and diabetes mellitus combined with comorbid
depression (DD).
Methods: Adult patients who were diagnosed with DM, DN, or DD were included in the study.
There were 55,972 patients in the DM cohort, 2,146 in the DN, and 2,379 in the DD. P values for
comparisons between the three mutually exclusive cohorts were conducted using the Tukey-
Kramer method. Cost comparisons among the cohorts were conducted using a stepwise
multivariate regression that controlled for patient characteristics and comorbid conditions.
Results: Individuals in the DM or DN cohorts were generally more likely to use antidiabetic
medications than patients in the DD group. Those diagnosed with DN or DD generally used more
pain medications than individuals in the DM cohort. The DM cohort had significantly lower
diabetes-related total medical costs ($1,297 v $5,125, p < 0.0001) and lower total medical costs
($4,819 v $24,765, p < 0.0001) than the DN cohort. The DM cohort also had significantly lower
diabetes-related total medical costs ($1,297 v $3,264, p < 0.0001) as well as significantly lower total
medical costs ($4,819 v $19,298, p < 0.0001) than the DD cohort.
Conclusion:  Results from this study indicated significant differences in demographic
characteristics, comorbidities, and medication use among individuals diagnosed with DM, DN, or
DD. These differences translated into significant cost differences. Patients diagnosed with DN or
DD had higher diabetes-related costs than patients diagnosed with DM.
Background
Diabetes was the sixth leading cause of death in the U.S.
in 2002 [1]. Between 1990 and 2000 the number of peo-
ple in the U.S. diagnosed with diabetes increased by 49%
[2]. An estimated 18.2 million Americans now suffer with
the disease, with 13 million diagnosed and 5.2 million
undiagnosed [1]. Accompanying this rise in prevalence is
a corresponding rise in the costs of managing the illness.
For example, the estimated cost of diabetes in the U.S.
increased from $98 billion in 1997 [3] to $132 billion in
2002 [4]. These costs represented direct medical expendi-
tures as well as lost productivity. If diabetes prevalence
rates were to remain at current levels, the Census Bureau
estimates that the number of people diagnosed with dia-
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betes would increase to nearly 14.5 million by 2010 and
to 17.4 million by 2020 [5]. The corresponding annual
cost of the illness (in 2002 dollars) would be an estimated
$156 billion in 2010 and $192 billion in 2020 [6].
Individuals diagnosed with diabetes mellitus [DM] also
may suffer from a wide array of physical complications,
such as kidney failure, blindness, lower limb amputa-
tions, heart disease, and stroke [7]. Diabetic neuropathy is
one of the most common long-term complications of dia-
betes mellitus. Diabetic neuropathy [DN] has the highest
morbidity and mortality rates [8] and is associated with a
substantial reduction in quality of life [9]. Approximately
10% of patients have neuropathy at the time of diabetes
diagnosis [10,11], and that number increases to as much
as 50% among patients who have had diabetes for 15 or
more years [10,12].
In addition to physical complications associated with dia-
betes, individuals with diabetes are also at an increased
risk for mental health disorders, particularly depression
[13,14]. For example, research has shown that individuals
diagnosed with type 2 diabetes were 60% more likely to
be diagnosed with depression than patients without type
2 diabetes [15]. Similar results were reported among eld-
erly Medicare claimants [16]. A diagnosis of diabetes and
comorbid depression [DD] has been shown to be associ-
ated with poor metabolic control, reduced adherence to a
medication regime, decreased quality of life [17-19], and
higher medical costs [16].
Antidepressants are often prescribed for the treatment of
DD as well as for the pain that accompanies DN [20].
Alternatively, medications such as narcotics or non-steroi-
dal anti-inflammatory drugs (NSAIDs) may also be pre-
scribed to help alleviate pain associated with DN or DM.
Given the high rate of comorbid depression that accom-
panies a diagnosis of diabetes and the large percentage of
diabetic patients who are eventually diagnosed with dia-
betic neuropathy, the use of such antidepressants and
pain medications may add significantly to costs associated
with a diagnosis of diabetes.
The purpose of this study was to examine the impact of a
serious physical complication (diabetic neuropathy) and
a common mental-health related comorbidity (depres-
sion) in the diabetes population. To this end, the study
compares patients diagnosed with diabetes mellitus
(DM), diabetic neuropathy (DN), and diabetes mellitus
combined with comorbid depression (DD) to detect pat-
terns and differences in 1) demographic characteristics; 2)
the use of antidiabetic medications, antidepressants, and
pain medications; and 3) direct medical costs. Findings in
this study can therefore be used to help administrators of
managed care plans understand resource utilization
among a growing sub-group of their population and can
also be used for patient-level economic models of diabe-
tes and diabetes-related comorbidities and complications.
Methods
Data for this study was obtained from the PharMetrics
Patient-Centric Database. This Health Insurance Portabil-
ity and Accountability Act-compliant database integrates
enrollment, medical, and prescription claims data. The
database is a systematic sample of commercial health plan
information obtained from managed care plans through-
out the United States that contains information from over
75 different managed care organizations and consists of
more than 55 million lives. All data is standardized across
different sources and goes through a rigorous data quality
review. For this study, we considered data from the time
period January 1, 1995 through August 22, 2003.
The diabetes cohort (DM) consisted of individuals who
were first diagnosed with diabetes (based upon an ICD-9
code of 250.0x–250.5x and 250.7x–250.9x) or first
received an antidiabetic agent during the time period cov-
ering July 1, 1995 through August 23, 2002 (e.g. the iden-
tification period), with the first such date identified as the
index date. The identification period begins six months
after the start period of the data used in the analysis and
ends one year prior to the end of the data in order to allow
for a six month pre-period and twelve month post-period.
In addition, in order to be included in the DM cohort,
individuals could not have been diagnosed with either
depression (based upon an ICD-9 code of 296.2x, 296.3x,
300.4x, 309.0x, 309.1x or 311.xx) or diabetic neuropathy
(based upon an ICD-9 code of 205.6x) and to be contin-
uously insured from the beginning of the pre-period
through the end of the post-period. There were 55,972
individuals who fit the above criteria. Similarly, for inclu-
sion in the DN cohort (N = 2,146), individuals were first
diagnosed with diabetic neuropathy during the identifica-
tion period, were not diagnosed with depression, and had
continuous insurance coverage from six months prior
through twelve months post index date.
For inclusion in the DD cohort, individuals had to be
diagnosed with both diabetes and depression. Individuals
first diagnosed with diabetes or receiving an antidiabetic
medication during the index period were required to have
a diagnosis of depression in both the pre-period and the
post-period. Alternatively, individuals first diagnosed
with depression during the index period were required to
have a diagnosis of diabetes or receipt of an antidiabetic
medication during both the pre-period and the post-
period. These criteria were employed in order to insure
that the index date represents the date of comorbid diabe-
tes and depression. In addition, individuals in the DD
cohort were required to not be diagnosed with diabeticCost Effectiveness and Resource Allocation 2006, 4:18 http://www.resource-allocation.com/content/4/1/18
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neuropathy and to have continuous insurance coverage
from six months pre through twelve months post index
date. There were 2,379 individuals in the DD cohort.
The analysis examined differences in patient characteris-
tics, comorbidity profiles, utilization of medications
(antidiabetic, antidepressant, and pain-relieving), and
direct medical costs across the DM, DN, and DD cohorts.
Patients were identified as having a comorbid condition if
they were diagnosed with the condition at any time dur-
ing the six month pre-period. Direct medical costs were
calculated as the sum of all payments and were converted
to 2003 values using the medical services component of
the consumer price index. Diabetes related costs were
defined as a payment associated with a diagnosis of diabe-
tes (whether primary or secondary diagnosis) as well as
payments for any antidiabetic medication.
Patient characteristics and medication use were examined
for both the DN and DD cohorts compared to the DM
cohort as well as between the DN and DD cohorts. P val-
ues for differences across cohorts were constructed using
the Tukey-Kramer method in order to adjust for multiple
pairwise testing. To examine costs between cohorts, mul-
tivariate ordinary-least-squares stepwise regressions were
estimated controlling for patient characteristics and
comorbidities diagnosed in the six months prior to the
index date. The logs of costs were used as the dependent
variable in order to account for the skewed nature of cost
data. From these regression results, costs associated with a
diagnosis of DD or DN compared to DM were estimated
as were costs associated with a diagnosis of DN compared
to DD. All analyses were conducted using SAS Version 9.1
[21].
Results
Patients in the DN cohort were older than in the DM
(with a mean age of 51 yrs vs. 47 yrs, p < 0.0001) or the
DD cohort (51 yrs vs. 47 yrs, p < 0.0001), while there was
no statistical difference in age between the DM and DD
cohorts (p = 0.4626). Whereas over half of the DM and
DN patients were males (51%), over half of the DD
patients (63%) were females. A majority of the patients
were diagnosed in either the South or Midwest and were
commercially insured or self-insured (see Table 1).
The most common comorbidities in all three cohorts were
hypertension, hyperlipidemia, and cardiovascular dis-
eases. DM patients had a significantly lower rate of hyper-
tension, hyperlipidemia, and cardiovascular diseases
compared to patients with DN or DD; however, there
were no significant difference between DN and DD
patients in the prevalence of hypertension or hyperlipi-
demia (see Table 1). With the exception of obesity, indi-
viduals in the the DN cohort were most likely to have any
of the comorbid diagnoses examined, while patients diag-
nosed with diabetes and comorbid depression were signif-
icantly more likely to be diagnosed as obese.
Generally, the three most commonly prescribed antidia-
betic medications were metformin, glipizide, and glybu-
ride. These medications were three of the four most
commonly prescribed medications for DN patients, with
insulin lispro being the second most prescribed medica-
tion (see Table 2). Considering classes of medications,
sulfonylureas and meglitinides were most commonly pre-
scribed in all three cohorts. Generally, individuals in the
DN or DD cohorts were more likely to receive an antidia-
betic medication than those in the DM cohort and there
were little differences in prescribing of antidiabetic medi-
cations between the DN and DD cohorts.
Not only were there differences in the cohorts with regards
to use of antidiabetic medications, but there were also dif-
ferences in the use of pain medications (see Table 3). The
DD cohort used the most antidepressants; however, anti-
depressant use among the other cohorts was also non-triv-
ial, with 10.68% of the DM cohort and 41.33% of the DN
cohort using an antidepressant. A comorbid diagnosis of
depression or diabetic neuropathy was associated with a
significantly higher use of antidepressants, anticonvul-
sants, skeletal-muscle relaxants, non-narcotic pain medi-
cation, narcotics, and NSAIDs. The DD patients were
significantly more likely to use a non-narcotic than the
DN patients, while there were no significant differences in
anticonvulsant, skeletal-muscle relaxant, narcotic, or
NSAID use between the two cohorts.
Patients diagnosed with DM, DN, or DD had significant
differences in total medical costs (see Table 4). Patients in
both the DN and DD cohorts had significantly higher
mean total medical costs than DM patients ($24,765 vs.
$4,819, $19,398 vs. $4,819, p < 0.0001). This increase in
costs associated with a diagnosis of neuropathy included
all cost components: inpatient ($7,282 vs. $1,005, p-
value < 0.0001), outpatient ($14,137 vs. $2,548, p-value
< 0.0001), emergency room ($889 vs. $178, p-value <
0.0001), and pharmaceutical ($6,526 vs. $1,098, p-value
< 0.0001) costs. Similarly, all cost components were also
higher in the DD cohort relative to the DM cohort. A com-
parison of the DN and DD cohorts revealed that there
were significantly higher inpatient ($4,167 vs. $3,011, p <
0.01) and outpatient ($8,862 vs. $8,109, p < 0.05) costs
in the DN cohort, and no significant difference in total
direct medical costs, emergency room costs or pharmaceu-
tical costs.
Patients diagnosed with DM had a mean total diabetes
related medical cost of $1,297; however, with the addi-
tion of a neuropathy complication or comorbid diagnosisCost Effectiveness and Resource Allocation 2006, 4:18 http://www.resource-allocation.com/content/4/1/18
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of depression, the mean total diabetes related costs were
significantly increased, to $5,125 (p-value < 0.0001) for
DN patients and $3,263 (p-value < 0.0001) for DD
patients (see Table 4). The DN cohort also had signifi-
cantly higher diabetes related medical costs compared to
the DD cohort ($3,456 vs. $2,783, p-value < 0.0001). As
a test of the robustness of the results, the multivariate cost
regressions were reestimated with a 10% trim of the data
in order to minimize the potential impact of outliers.
General results were not sensitive to this alternative spec-
ification.
The analysis also briefly examined a small cohort of 683
diabetic patients diagnosed with both diabetic neuropa-
thy and depression. The cohort consisted of mostly
females (60%) and had a mean age of 49 years. The most
common antidiabetic medications for patients with neu-
ropathy and depression were metformin (59.44%), insu-
lin lispro (36.16%), glyburide (29.43%) and glipizide
(26.65%%). In addition to the antidiabetic medications,
77% received a prescription for narcotic medications,
61% for NSAIDs, and 34% for anticonvulsants. Total costs
for individuals diagnosed with diabetic neuropathy and
depression were over twice as much for those in the DN
cohort ($48,281 vs. $18,665, p < 0.0001) and triple the
direct medical costs for individuals with DD ($47,214 vs.
$14,785, p < 0.0001).
Table 1: Patient Characteristics
Patient Characteristic Diabetes (N = 55,972) Diabetic Neuropathy 
(N = 2,146)
Diabetes and 
Depression
(N = 2,379)
P-Values
Mean Std Dev Mean Std Dev Mean Std Dev DM v DN DM v DD DN v DD
Mean Age 46.67 15.53 50.69 13.35 47.05 12.99 * 0.4626 *
Sex N % N % N %
Female 27,229 48.65 1,043 48.60 1,501 6.39 0.9991 * *
Male 28,743 51.35 1,103 51.40 878 36.91 0.9991 * *
Region
East 12,134 21.68 273 12.72 282 11.85 * * 0.7533
Midwest 17,044 30.45 813 37.88 1,100 46.24 * * *
South 21,468 38.35 902 42.03 592 24.88 *** * *
West 5,362 9.52 158 7.36 405 17.02 *** * *
Payment Type
Commercial 17,820 31.84 670 31.22 875 36.78 0.8196 * **
Medicaid 1,143 2.04 45 2.10 188 7.90 0.9846 * *
Medicaid Risk 4,158 7.43 242 11.28 137 5.76 * *** *
Self-Insured 10,748 19.20 249 11.60 189 7.94 * * ***
Other 22,103 37.49 940 43.80 990 41.61 ** 0.0952 0.2898
Comorbidities
Hypertension 13,578 24.27 975 45.43 1,076 48.23 * * 0.9863
Hyperlipidemia 5,354 9.57 440 20.50 494 20.77 * * 0.9549
Cardiovascular Disease 4,457 7.96 565 26.33 494 20.77 * * *
Ischemic Heart Disease 2,737 4.89 342 15.94 313 13.16 * * *
Obesity 1,668 2.98 130 6.06 236 9.92 * * *
Retinopathy 910 1.63 299 13.93 168 7.06 * * *
Cataracts 840 1.50 119 5.55 109 4.58 * * ***
Diabetic Retinopathy 787 1.41 281 13.09 150 6.31 * * *
Nephropathy 374 0.67 110 5.13 60 2.52 * * *
Osteoporosis 372 0.66 43 2.00 46 1.93 * * 0.9603
Arteriosclerosis 259 0.46 86 4.01 42 1.77 * * *
Blindness 45 0.08 8 0.37 7 0.29 * *** 0.6792
Gangrene 37 0.07 32 1.49 8 0.34 * ** *
Dialysis 15 0.04 8 0.37 3 0.13 * 0.0572 **
*P-value ≤ 0.0001; **P-value ≤ 0.001; ***P-value ≤ 0.05.
P values based on Tukey-Kramer method to adjust for multiple comparisons.Cost Effectiveness and Resource Allocation 2006, 4:18 http://www.resource-allocation.com/content/4/1/18
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Discussion
Results from this study indicated significant differences in
demographic characteristics, comorbidities, and medica-
tion use among individuals diagnosed with DM, DN, or
DD. An examination of demographic characteristics of
individuals in the DM, DN, and DD cohorts revealed that
the DD cohort was most likely to be female, most likely to
reside in the Midwest, and least likely to be self-insured.
These findings are consistent with previous research that
has found an increased prevalence of depression in
females [22,23]. An examination of patient characteristics
also revealed that individuals in the DN cohort, in most
cases, were most likely of the three cohorts to be diag-
nosed with complications or comorbidities; therefore, the
DN patients may be complicated to treat, and special
attention may need to be paid to possible medication
interactions.
The study cohorts used a variety of antidiabetic medica-
tions. For all cohorts, the most commonly prescribed anti-
diabetic medication was metformin and the second-
generation sulfonylureas glyburide and glipizide were
also frequently prescribed. While previous research has
found that metformin is associated with decreased mor-
tality [24,25], reductions in any diabetes-related endpoint
[25], and improved glycemic control [26], other research
has found that compared to sulfonylureas, metformin is
not as cost-effective [27,28]. In contrast, a study of the Vet-
eran's Administration found that in 1998 and 2000 the
second-generation sulfonylureas were most commonly
prescribed, although the percentage of users was decreas-
ing over time [29]. There was relatively little use of insulin
by individuals in the DM cohort with only 5% of the DM
cohort using any insulin. In contrast, 23% of the DN
cohort and 16% of the DD cohort received insulin during
the twelve month post-period. While the use of insulin
was less, on average, than found in the Department of Vet-
eran Affairs (VA) study, this population was younger and
more predominantly female than the VA population [29].
In addition to an examination of the antidiabetic medica-
tions used by individuals diagnosed with DM, DN, or DD,
pharmacological treatments that are often used to treat
painful physical symptoms were also examined. These
medications, which include antidepressants, anticonvul-
sants, skeletal-muscle relaxants, non-narcotics, narcotics,
and NSAIDs have been examined previously in the use of
the management of neuropathic pain [30]. Of course,
antidepressants may also be used independently for the
treatment of depression that may be comorbid with dia-
Table 2: Frequency of Use of Anti-Diabetic Medications
Anti-Diabetic Medications Diabetes (N = 55.972) Diabetic Neuropathy 
(N = 2,146)
Diabetes and 
Depression 
(N = 2,379)
P-Value
N % N % N % DM v DN DM v DD DN v DD
Sulfonylurea
Glimepiried 2,821 5.04 180 8.29 192 8.07 * * 0.8823
Glipizide 9,034 16.14 458 21.34 554 23.29 * * 0.1846
Glyburide 7,446 13.30 451 21.02 466 19.59 * * 0.3454
Any Sulfonylurea 18,207 32.53 924 43.06 1,072 45.06 * * 0.3253
Meglitinide
Nateglinide 222 0.40 19 0.89 6 0.25 *** 0.5252 ***
Repaglinide 863 1.54 63 2.94 1 2.27 * *** 0.1790
Any Meglitinide 1,078 1.93 82 3.32 60 2.52 * 0.1059 ***
Biguanide
Metformin HCL 15,744 28.13 952 44.36 1,072 45.06 * * 0.8625
Thiazolidinedione
Pioglitazone HCL 2,371 4.24 227 10.58 233 9.79 * * 0.4238
Rosiglitazone Maleate 3,073 5.49 287 13.37 292 12.27 * * 0.2650
Any Thiazolidinedione 5,283 9.44 491 22.88 494 20.77 * * ***
Alpha Glucose Inhibitor
Acarbose 256 0.46 13 0.61 18 0.76 0.5883 0.0939 0.7412
Miglitol 112 0.20 13 0.61 1 0.04 ** 0.2222 *
Any Alpha Glucose Inhibitor 363 0.65 26 1.21 19 0.80 *** 0.6553 0.2072
Insulin
Insulin Glargine 272 0.49 68 3.17 75 3.15 * * 0.9976
Insulin Lispro 2,837 5.07 469 21.85 359 15.09 * * *
Any Insulin 2,940 5.25 493 22.97 381 16.02 * * *
*P-value ≤ 0.0001; **P-value ≤ 0.001; ***P-value ≤ 0.05.
P values based on Tukey-Kramer method to adjust for multiple comparisons.Cost Effectiveness and Resource Allocation 2006, 4:18 http://www.resource-allocation.com/content/4/1/18
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betes. Among all cohorts, SSRIs were the most commonly
prescribed class of antidepressant, although results also
indicated that individuals in the DD cohort were more
likely to use SSRIs, while those with DN were more likely
to use tricyclics. This finding is consistent with the evi-
dence that SSRIs are well suited for the treatment of
depression [31-33] and that tricyclics may be more effec-
tive at treating neuropathic pain [30] than SSRIs. Given
the painful symptoms that may accompany diabetic neu-
ropathy, it is not surprising that the DN cohort used sig-
nificantly more pain medications than the DM cohort.
The DD cohort also used significantly more of all classes
of pain medications than the DM cohort and significantly
more antidepressants than the DN cohort. This finding
complements previous research that has found signifi-
cantly higher prescription medication expenditures for
individuals diagnosed with DD compared to a DM cohort
[34], by illustrating some significant differences in the use
of specific medications between the two groups.
The difference in patient characteristics, use of antidia-
betic medications, and use of pain medications between
the three cohorts translated into significant differences in
medical costs. Individuals diagnosed with DD had signif-
icantly higher total medical costs related to a diagnosis of
diabetes, as well as higher total medical costs. These
higher total medical costs consisted of significantly higher
inpatient, outpatient, emergency room, and pharmaceuti-
cal costs for individuals diagnosed with DD. Prior
research has found that individuals diagnosed with diabe-
tes and comorbid depression are less likely to exercise,
maintain a healthy diet, or adhere to oral hypoglycemic
medication [35]. Given these outcomes associated with
DD it is not surprising that this research, as well as other
research, has found higher costs associated with comorbid
depression [18,34].
Individuals diagnosed with DN had significantly higher
costs than individuals diagnosed with DM, with total
direct medical costs for DN more than five times higher
than costs associated with DM. These costs are consistent
with previous research, which has found significantly
higher costs associated with diabetic complications [36-
38]. In addition to the higher total medical costs associ-
ated with DN, individuals in the DN cohort also had sig-
nificantly higher diabetes-related costs compared to
Table 3: Frequency of Use of Pain Medications
Pain Medications Diabetes (N = 55,972) Diabetic 
Neuropathy
(N = 2,146)
Diabetes and 
Depression
(N = 2,379)
P-Value
N % N % N % DM v DN DM v DD DN v DD
Antidepressants
SSRI 3,376 6.03 536 24.98 1,346 56.58 * * *
Tricyclic 1,884 3.37 366 17.05 354 14.88 * * **
Venlafaxine 271 0.48 58 2.70 216 9.08 * * *
Bupropion 750 1.34 109 5.08 333 14.00 * * *
Other Antidepressant 641 1.15 127 5.92 414 17.40 * * *
Any Antidepressant 5,979 10.68 887 41.33 1,715 72.09 * * *
Anticonvulsant
Gabapentin 867 1.55 286 13.33 197 8.28 * * *
Other Anticonvulsant 911 1.63 137 6.38 273 11.48 * * *
Any Anticonvulsant 1,669 2.98 388 18.08 414 17.40 * * 0.4693
Skeletal-Muscle Relaxants 3,623 6.47 349 16.26 404 16.98 * * 0.6165
Non-Narcotics 1,018 1.82 88 4.10 134 5.63 * * **
Narcotics
Oxycodone 2,789 4.98 370 17.24 353 14.84 * * ***
Tramadol 1,043 1.86 129 6.01 144 6.05 * * 0.9949
Codeine 3,128 5.59 300 13.98 306 12.86 * * 0.2611
Hydrocodone-Acetaminophen 5,545 9.91 528 24.60 645 27.11 * * ***
Proxyphene 3,374 6.03 350 16.31 369 15.51 * * 0.5303
Other Narcotics 1,051 1.88 121 5.64 150 6.31 * * 0.2740
Any Narcotics 12,383 22.12 1,065 44.63 1,152 48.42 * * 0.6036
NSAIDs
Cox-2 4,445 7.94 355 16.54 407 17.11 * * 0.7753
Other NSAID 10,005 17.88 761 35.46 823 34.59 * * 0.7367
Any NSAID 12,839 22.94 938 43.71 1,040 43.72 * * 1.00
*P-value ≤ 0.0001; **P-value ≤ 0.001; ***P-value ≤ 0.05
P values based on Tukey-Kramer method to adjust for multiple comparisons.Cost Effectiveness and Resource Allocation 2006, 4:18 http://www.resource-allocation.com/content/4/1/18
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individuals diagnosed with DM or DD. For example, indi-
viduals with DN had 25% higher diabetes-related costs
than those diagnosed with DD. Previous research has also
found that being diagnosed with neuropathy was linked
to significantly higher diabetes related costs [39]. While
little research has directly compared the costs associated
with DN to the costs associated with DD, this study gen-
erally found that resource utilization and medical costs
associated with DN were significantly higher than those
associated with DD.
Prior research has examined the impact of diabetes by
comparing costs for individuals with and without diabe-
tes. Some studies have examined the impact of diabetes
on society by comparing total direct and indirect health-
care costs associated with a diabetes diagnosis [40,41].
Other studies have examined the impact of diabetes on
employers by examining incremental productivity costs as
well as medical costs of the disease [42]. Prior research has
also examined the impact of diabetic complications and
comorbid diagnoses in the aggregate, but without narrow-
ing the analysis to any specific complication or set of
comorbidities [3,43]. For example, such research has pro-
duced estimates of the costs associated with chronic dia-
betic complications in the U.S. that range from $12 to $18
billion dollars.
In addition to examining the economic impact of diabe-
tes, previous research has also examined the economic
impact of diabetes with comorbid depression and diabetic
neuropathy. For example, prior research has compared
healthcare costs associated with a diagnosis of diabetes to
costs for individuals with diabetes and comorbid depres-
sion and found that patients with depression had higher
total healthcare costs than individuals diagnosed with
diabetes and no comorbid depression [34,44,45]. While
research has consistently found higher costs associated
with comorbid diagnosis of depression, estimates of the
amount of increased costs have varied widely. For exam-
ple, the range of the increased costs for a comorbid diag-
Table 4: Medical Costs
Diabetic Neuropathy (DN) Cohort Compared to Diabetes (DM) Cohort
Cost Component Comparative Costs P Value
Total Direct Medical Costs $4819.29 v $24,764.91 *
Inpatient Costs $1,004.78 v $7,282.16 *
Outpatient Costs $2,548.09 v $14,137.98 *
ER Costs $178.28 v $889.25 *
Pharmaceutical Costs $1,098.28 v $5,622.53 *
Diabetes-Related Total Direct Medical Costs $1,296.79 v $5,125.10 *
Diabetes and Depression (DD) Cohort Compared to Diabetes (DM) Cohort
Cost Component Comparative Costs P Value
Total Direct Medical Costs $4,819.29 v $19,397.59 *
Inpatient Costs $1,004.78 v $3,644.51 *
Outpatient Costs $2,548.09 v $10,895.46 *
ER Costs $178.28 v $833.85 *
Pharmaceutical Costs $1,098.28 v $6,526.86 *
Diabetes-Related Total Direct Medical Costs $1,296.79 v $3,263.81 *
Diabetic Neuropathy (DN) Cohort Compared to Diabetes and Depressed (DD) Cohort
Cost Component Comparative Costs P Value
Total Direct Medical Costs --- NS
Inpatient Costs $3,011.01 v $4,167.12 **
Outpatient Costs $8,109.09 v $8,861.53 ***
ER Costs --- NS
Pharmaceutical Costs --- NS
Diabetes-Related Total Direct Medical Costs $2,783.23 v $3,455.54 *
Results from ordinary least squares, stepwise regressions controlling for age, sex, region, insurance type, and comorbidities (hypertension, 
hyperlipidemia, cardiovascular disease, ischemic heart disease, and obesity) using log of costs as the dependent variable.
*P-value ≤ 0.0001; **P-value ≤ 0.001; ***P-value ≤ 0.05Cost Effectiveness and Resource Allocation 2006, 4:18 http://www.resource-allocation.com/content/4/1/18
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nosis of depression ranges from 65% [44] to 350% [34].
Similarly, research has also shown significantly higher
medical costs associated with diabetic neuropathy, with
prior research estimating that among all patients diag-
nosed with diabetes, diabetic neuropathy is associated
with 17% [46] to 27% [39] of the direct medical costs of
diabetes.
One advantage of this current research is that the use of
pairwise comparions allows for an examination of the rel-
ative impact of diabetic neuropathy or diabetes with
comorbid depression compared to a diagnosis of diabe-
tes. As such, the research provides additional evidence
concerning the relative impact that comorbid depression
or diabetic neuropathy has on resource utilization in gen-
eral and medical costs in particular. In addition, the anal-
yses also compared the relative impact of diabetes and
depression to diabetic neuropathy and briefly examined
the incremental costs associated with individuals who
have been diagnosed with both diabetic neuropathy and
comorbid depression. This research also allows for a more
thorough understanding of resource utilization by look-
ing at the use of antidiabetic medications, commonly pre-
scribed pain medications, as well as direct medical costs,
major components of direct medical costs, and diabetes-
related direct medical costs.
The findings of this study should be interpreted in the
context of the limitations of the study design. First, this
study was conducted using an administrative claims data-
base and included only patients with medical and pre-
scription benefit coverage; therefore, the results may not
be generalizeable to other populations. Second, the use of
diagnostic codes to identify individuals is not as rigorous
as formal diagnostic assessments for identifying people
with diabetic neuropathy or depression. In addition, the
database used in this study did not allow for a categoriza-
tion of primary or secondary diagnoses. Therefore, diabe-
tes- related total direct medical costs were constructed
from any diagnoses of diabetes. While this methodology
may likely bias the estimates of diabetes related costs
upwards, there is no reason to believe that it would bias
the relative difference in diabetes-related costs among the
DM, DN and DD cohorts. Third, the use of medical claims
data precludes the use of patient assessments; as a result,
the analysis cannot examine quality of life, functioning, or
any clinical outcomes. Finally, the analyses focused exclu-
sively on resource utilization and direct medical costs
associated with a diagnosis of diabetes, diabetes with neu-
ropathy, and diabetes with comorbid depression; there-
fore, it did not include any other potentially important
costs, such as productivity costs and caregiver burden.
Conclusion
In conclusion, this retrospective database study compared
patient characteristics, medication use, and direct medical
costs in diabetic patients with and without complications
of neuropathy and comorbid depression. There were sig-
nificant differences in comorbidities and medication use
among the three study cohorts. These differences trans-
lated into significantly higher direct medical costs for
individuals diagnosed with a diabetic complication of
neuropathy or with comorbid depression.
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